PTC Therapeutics, Inc.
PTCT
$71.70
-$0.27-0.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -42.84% | -53.34% | 114.51% | 97.54% | 96.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -42.84% | -53.34% | 114.51% | 97.54% | 96.00% |
| Cost of Revenue | -9.79% | -12.48% | -15.14% | -16.31% | -7.16% |
| Gross Profit | -58.19% | -73.36% | 471.61% | 326.20% | 304.88% |
| SG&A Expenses | 7.21% | 14.18% | 15.36% | 14.51% | 8.14% |
| Depreciation & Amortization | 183.80% | 150.08% | -59.26% | -86.11% | -92.53% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -0.59% | -1.04% | -8.32% | -16.68% | -17.82% |
| Operating Income | -86.63% | -107.82% | 683.66% | 821.89% | 550.40% |
| Income Before Tax | -110.07% | -136.18% | 291.84% | 274.16% | 234.82% |
| Income Tax Expenses | -177.73% | -186.53% | 7,840.34% | -138.66% | 353.65% |
| Earnings from Continuing Operations | -106.10% | -131.39% | 287.90% | 265.87% | 231.21% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -106.10% | -131.39% | 287.90% | 265.87% | 231.21% |
| EBIT | -86.63% | -107.82% | 683.66% | 821.89% | 550.40% |
| EBITDA | -80.87% | -102.33% | 1,359.53% | 4,270.83% | 6,935.62% |
| EPS Basic | -106.21% | -130.87% | 285.92% | 261.83% | 227.01% |
| Normalized Basic EPS | -110.58% | -131.46% | 408.94% | 398.51% | 324.40% |
| EPS Diluted | -108.52% | -136.00% | 263.27% | 243.81% | 210.22% |
| Normalized Diluted EPS | -112.77% | -134.98% | 370.05% | 369.11% | 299.49% |
| Average Basic Shares Outstanding | 4.61% | 3.52% | 2.63% | 2.06% | 2.07% |
| Average Diluted Shares Outstanding | 7.43% | 3.54% | 8.13% | 7.60% | 4.79% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |